Prediction: BridgeBio Pharma Will Beat the Market. Here's Why
Explore the exciting world of BridgeBio Pharma (NASDAQ: BBIO) with our expert analysts in this Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...
Dealbreaker on MSN10h
BridgeBio Oncology to Go Public in SPAC Deal Bringing $450 Million-Plus for Trio of Cancer Drugs
Clinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...
The Pharma Letter16h
BridgeBio spin-out in SPAC deal to target RAS and PI3Kα malignancies
BridgeBio Oncology Therapeutics (BBOT), a company advancing small molecule therapeutics targeting RAS and PI3Ka malignancies, ...
BridgeBio Oncology and Helix enter definitive merger agreement
BridgeBio Oncology has entered a definitive merger agreement with Helix Acquisition Corp II, which will result in the ...
Evercore ISI Reaffirms Their Buy Rating on Arcellx Inc (ACLX)
Evercore ISI analyst Cory Kasimov reiterated a Buy rating on Arcellx Inc (ACLX – Research Report) on February 28 and set a price target of ...